About BioXcel Therapeutics
BioXcel Therapeutics Inc. is a biopharmaceutical company leveraging artificial intelligence for drug re-innovation and development. The company focuses on identifying and developing breakthrough therapies primarily in neuroscience and immuno-oncology. BioXcel's proprietary AI-based drug re-innovation platform analyzes vast amounts of data to identify new therapeutic applications for existing drug candidates, accelerating the drug development process. The company's lead commercial product is IGALMI® (dexmedetomidine), an FDA-approved sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel is expanding IGALMI's indications through clinical trials, including the SERENITY At-Home Phase 3 trial for at-home use in agitation associated with bipolar disorders or schizophrenia. BioXcel Therapeutics serves healthcare providers, patients, and healthcare systems treating psychiatric and neurological conditions. The company operates through its subsidiary OnkosXcel Therapeutics for oncology programs. As a publicly traded company on NASDAQ, BioXcel combines cutting-edge AI technology with pharmaceutical expertise to address significant unmet medical needs in mental health and cancer treatment.
Clinical Focus
Medical conditions and clinical areas addressed by BioXcel Therapeutics.
Who It Serves
Milestones & Awards
Recent Milestones
SERENITY At-Home Phase 3 trial data presentation at 2026 ASCP Annual Meeting; Virtual event announced for commercial launch plan for IGALMI in at-home setting (April 2026); Q1 2026 financial results reported (May 2026)
Company Details
- Headquarters
- United States
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.